Background: Existing epidemiological studies illustrate that proton pump inhibitors (PPIs) may be related to adverse kidney outcomes. To date, no comprehensive meta-analysis has been conducted to evaluate and quantify this association. Methods: We performed a systematic review and meta-analysis of studies to assess the association between PPI use and the risk of adverse kidney outcomes. We searched MEDLINE, Embase, SCOPUS, Web of Science, CINAHL, Cochrane Library and grey literature with no language restrictions (through 31 October 2016). Adverse kidney outcomes were acute interstitial nephritis (AIN), acute kidney injury (AKI), chronic kidney disease (CKD) and end-stage renal disease (ESRD). The risk ratios (RRs) and confidence intervals (CIs) were pooled using a random effects model. The strength of evidence (SOE) for each outcome was assessed using the Grading of Recommended Assessment, Development and Evaluation system. Results: Of 2037 identified studies, four cohort and five casecontrol studies with $2.6 million patients were included. Of these, 534 003 (20.2%) were PPI users. Compared with non-PPI users, PPI users experienced a significantly higher risk of AKI [RR 1.44 
studies revealed that PPIs might elevate the risk of rare adverse events. These potential rare events are highlighted by the US Food and Drug Administration and Health Canada and include bone fractures, Clostridium difficile infection and hypomagnesemia [16] [17] [18] . PPIs have also been associated with community-acquired pneumonia, spontaneous bacterial peritonitis and dementia [19] [20] [21] .
In addition, previous studies illustrated that PPIs may be associated with adverse kidney outcomes [22] [23] [24] [25] [26] . A large population-based study found a relationship between PPI use and the risk of acute interstitial nephritis (AIN) and acute kidney injury (AKI) [27] . Recently, prior studies on US cohorts were extended and demonstrated an association between longterm PPI usage and chronic kidney disease (CKD), probably mediated through AIN, recurrent AKI and hypomagnesemia [28] [29] [30] . Despite growing concern about the association between PPIs and adverse kidney outcomes, no systematic review or meta-analysis of this topic has been conducted. This study was therefore conducted to systematically review and synthesize the association between PPI use and the risk of adverse kidney outcomes. Evidence from this study can be used to promote rational prescriptions of PPIs in institutional and community settings.
M A T E R I A L S A N D M E T H O D S
This systematic review and meta-analysis was conducted in accordance with the Method Guide for Effectiveness and Comparative Effectiveness Reviews, 2014 Edition [31] and the Meta-analysis of Observational Studies in Epidemiological Guidelines (Supplementary Data, Table S1 ) [32] .
Search strategy
An experienced information specialist developed electronic search strategies using an iterative process and in collaboration with the search team. We searched electronic databases, including MEDLINE, Embase, SCOPUS, Web of Science, CINAHL and the Cochrane Library, from inception to 31 October 2016. The search strategy included pharmacological class or individual PPIs (e.g. proton pump inhibitors, omeprazole, esomeprazole, rabeprazole, pantoprazole, lansoprazole, dexlansoprazole) and adverse kidney outcomes (e.g. acute interstitial nephritis, acute kidney injury, chronic kidney disease, end-stage renal disease). Details of the search strategies are described in Online Appendix S1.
Grey literature from ClinicalTrial.gov, Google Scholar and jane.biosemantics.org were sought from inception to 31 October 2016 for the identification of additional studies. We also searched for the abstracts of conference proceedings from the major international nephrology and gastroenterology congresses (European Renal Association-European Dialysis and Transplant Association, American Society of Nephrology, International Society of Nephrology, American Gastroenterology Association, American College of Gastroenterology) between 2012 and 2016. Relevant studies were also sought from reference lists of included studies and prior systematic reviews.
Study selection and outcome measures
Eligible titles/abstracts and relevant full-text articles were screened independently by two investigators. A third party verified the accuracy. Any disagreement was resolved through a team discussion and/or consultation with the principal investigator (C.R.).
We included both experimental and observational studies that (Supplementary Data, Table S2 ) (i) evaluated the association between PPI use for any indications and the risk of adverse kidney outcomes, (ii) consisted of two or more groups in which one group represented PPI users and (iii) reported adverse kidney outcomes. We excluded studies that (i) were crosssectional, case series/case reports, (ii) had no control group and (iii) included individuals who had a history of end-stage renal disease (ESRD) or received renal replacement therapy at the baseline. For studies with overlapping participants, the data with the longest duration, the most detailed information and/or the most relevant information were included.
The following adverse kidney outcomes were included: AIN, AKI, CKD and ESRD. Definite cases of AIN were defined as patients who presented with AIN, confirmed through pathologic results. The incidence of AKI, CKD and ESRD was defined according to the most recent Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [33, 34] . However, we defined the outcomes according to each study. If data were available, individual PPI use and dosage were investigated to explore the evidence of dose-and duration-response effects.
Data extraction
Two investigators independently extracted data using a predesigned electronic extraction form, including study characteristics, participant characteristics, intervention and predefined adverse kidney outcomes. The two investigators verified the data. Any discrepancies were resolved through a team discussion. For studies with missing data or uncertain information, the corresponding author was contacted. If the authors did not respond, the study was excluded.
Risk of bias and grading the strength of evidence (SOE)
Two investigators independently appraised the risk of bias for each included study according to the study design. However, we did not identify any clinical controlled trials. The Newcastle-Ottawa Scale (NOS) was therefore used to assess the methodological quality of included observational studies [35] . Studies were categorized as the highest quality if the summary score was >8 points. To interpret the findings, the two investigators independently assessed the SOE for each outcome using the Grading of Recommended Assessment, Development and Evaluation (GRADE) system [36] . The SOE was ranked as insufficient, low, moderate or high. Any disagreements in the assessment of the risk of bias and grading of the SOE were resolved by a third reviewer.
Data synthesis
Only studies published in full-text were included in the data analysis to limit incomplete information [37] . However, to identify the potential influence of unpublished studies, post hoc meta-analysis was performed by adding relevant abstracts obtained from scientific meetings. For primary analysis, the risk of adverse kidney outcomes for PPI users was compared with that of non-PPI users. To maintain the consistency of result interpretations, histamine-2 receptor antagonists (H2RA) was identified as the active comparator in the secondary analysis.
When applicable, the relative risks (RRs) with the greatest degree of adjustment for potential confounding factors were identified as the common effect estimates of association across studies. The hazard ratios (HRs) were considered comparable to RRs. For studies that reported odds ratios (ORs), a corrected RR was computed using the methods described by Zhang and Yu [38] . The pooled RRs and 95% confidence intervals (CIs) were calculated using DerSimonian-Laird random effects models [39] . The number needed to harm (NNH) was calculated using event rates control from the Atherosclerosis Risk in Communities study, a prospective community-based cohort with an incidence of AKI and CKD among non-PPI users of 8.5% and 13.6%, respectively [29, 40] .
Furthermore, the population attributable risks (PARs) were calculated to estimate the percentage of patients at risk of adverse kidney outcomes with PPIs. The PARs were computed with the formula b[(rÀ1)/r], where b is the prevalence of PPI utilization and r is the pooled RRs estimated from the meta-analyses [41] . The prevalence of PPI utilization was derived from a national representative of the general population [42] [43] [44] . To approximate the number of individuals experiencing adverse kidney outcomes attributable to PPI use, we multiplied the PAR by the number of AKI and CKD cases worldwide, which was 13.3 and 497 million, respectively [45, 46] . Heterogeneity was evaluated by using the Cochran Q test, with P < 0.10. The I 2 index and s 2 statistics were used to estimate the degree of inconsistency [47] [48] [49] . The heterogeneity was indicated as low (I 2 25%, s 2 0.04), moderate (I 2 > 25% but < 75%, s 2 > 0.04 but < 0.36) or high (I 2 ! 75%, s 2 ! 0.36). A visually inspected funnel plot was used to investigate any evidence of publication bias. We also tested for funnel asymmetry using the Begg's and Egger's regression tests, with P < 0.10 [50, 51] . Additionally, the trim and fill method was employed to calibrate for publication bias [52] .
Preplanned subgroup analyses were performed based on the included studies and participant characteristics. Where possible, dose-and duration-response effects were also identified. Moreover, the level of risk of bias, study characteristics and baseline study-level characteristics were pre-specified and included in a random effects univariate meta-regression to explore heterogeneity.
To address the robustness of the findings, five types of sensitivity analyses were conducted by (i) using fixed-effects models, (ii) restricting the analysis to studies with the highest quality (NOS ! 8 points), (iii) adjusting for key confounding factors (baseline kidney function and NSAID use), (iv) removing individual study approaches and (v) stratifying the analysis according to analytical methods.
Statistical significance for all tests was two-tailed, with P < 0.05. All analyses were performed using STATA software version 14.0 (StataCorp, College Station, TX, USA).
R E S U L T S

Search strategy
The systematic literature search details are presented in Figure 1 . After screening all titles and abstracts, 110 full texts were retrieved and assessed for their eligibility against predefined inclusion/exclusion criteria. Of those, nine observational studies with 11 unique cohorts were evaluated ( Table 1 ). The grey literature search did not provide any additional relevant abstracts and unpublished studies. Detailed definitions of all outcomes and methods in the included studies are provided (Supplementary Data, Tables S3 and S4).
Characteristics of included studies
Approximately 2.6 million participants were involved. The baseline mean age ranged from 49.9 to 66.2 years and the majority of the included studies did not provide baseline kidney function. The characteristics of the included studies and participants are summarized in Table 1 and Supplementary Data, Tables S5 and S6. The distribution of individual PPI use and comedication use at the baseline are described in Supplementary Data, Tables S7 and S8, respectively. According to the risk of bias determined by NOS, most of the included studies had highquality summary scores ranging from 7 to 9 points (Supplementary Data, Table S9 ).
Adverse kidney outcomes
It was possible to pool four major adverse kidney outcomes, namely AIN, AKI, CKD and ESRD. The summary of findings and outcomes attributable to PPI utilization are illustrated in Tables 2 and 3 . However, a subgroup analysis for each individual PPI and a dose-and duration-response effects assessment could not be performed due to lack of data (Supplementary Data, Table S10 and S11).
AIN
The use of PPIs was associated with a significantly increased risk of AIN compared with no PPI use [three studies [24, 26, 27] , n ¼ 585 296, pooled RR 3.61 (95% CI 2.37-5.51); P < 0.001; Table 2 and Supplementary Data, Figure 1A ]. Because of limited data, it was impossible to perform a secondary analysis comparing PPIs to H2RA or to perform subgroup analysis.
AKI
Compared with non-PPI users, PPI users experienced a statistically higher risk of AKI [five studies [24, 25, 27, 29, 53] , n ¼ 2 140 913, pooled RR 1.44 (95% CI 1.08-1.91); P ¼ 0.013; NNH ¼ 27 (95% CI 13-147), Table 2 and Figure 2A ]. This significant and positive association existed even when H2RA was used as a comparator [pooled RR 1.32 (95% CI 1.17-1.51); P < 0.001; Table 2 and Supplementary Data, Figure 1B] . The PAR was found to range from 2.4 to 5.6%, suggesting that approximately 0.3-0.7 million cases with AKI worldwide were attributable to PPIs. However, the association between PPI use and AKI was insignificant in subgroup analyses where the
analysis was restricted to only case-control studies or non-US study locations (Supplementary Data).
CKD PPI users experienced a statistically higher risk of CKD compared with non-PPI users [four studies [28] [29] [30] 54] , n ¼ 689 953, pooled RR 1.36 (95% CI 1.07-1.72); P ¼ 0.012; NNH 20 (95% CI 10-105); Table 2 and Figure 2B ] and H2RA users [pooled RR 1.28 (95% CI 1.24-1.33); P < 0.001; Table 2 and Supplementary Data, Figure 1C ]. The PAR was estimated to range from 2.1% to 4.9%, indicating that approximately 10.4-24.4 million cases of CKD worldwide are attributable to PPI use. Nonetheless, our subgroup analyses revealed no association between PPI use and the risk of CKD among older patients (age > 62 years), studies with large sample sizes (> 10 000 participants), case-control studies and the US study location (Supplementary Data, Table S13 ).
ESRD
The primary analysis demonstrated that PPI use was associated with increased risk of ESRD compared with no PPI use [two studies [30, 54] , n ¼ 354 258, pooled RR 1.42 (95% CI 1.28-1.58); P < 0.001; Table 2 and Supplementary Data, Figure   1D ]. Owing to limited data, it was not possible to perform secondary and subgroup analyses.
Sensitivity analyses
For sensitivity analyses, we used fixed-effects models adjusted for key confounding factors (baseline kidney function and NSAID use). The stratified analysis performed according to the above analytical methods yielded main findings that were not significantly different. The summary results are provided in Supplementary Data, Tables S14, S15 and S16.
The positive association between PPI use and adverse kidney outcomes persisted even when we restricted our analysis to studies with the highest quality, except for AIN [RR 3.07 (95% CI 0.85-11.11); Supplementary Data, Table S17 ]. After the removal of the replication cohort studied by Lazarus et al. [29] , there was no association in AKI among PPI users and non-PPI users [RR 1.47 (95% CI 0.99-2.16)]. Furthermore, the association between PPI users and CKD became statistically insignificant after the study by Peng et al. [54] 
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Assessment of heterogeneity and publication bias
Two analyses with AKI and CKD demonstrated a moderateto-high degree of heterogeneity, with s 2 and the I 2 index exceeding 0.04% and 75%, respectively (Table 2, Figure 2A and B). However, this heterogeneity was substantially reduced when H2RA users were used as a comparator (P > 0.01 for the Cochran Q statistic; Table 2 ).
A univariate meta-regression was feasible for AKI and CKD. The effect estimates are shown in Supplementary Data, Table  S19 . Nevertheless, the heterogeneity of the included studies was not explained by any of the baseline study-level characteristics or the risk of bias for AKI and CKD outcomes. No evidence of asymmetry was observed in the results of the Begg's and Egger's regression tests, with P >0.01. The main results were not substantially different after calibration for publication bias by using the trim and fill method (Supplementary Data, Table S20 ). The visually inspected funnel plots are shown in Supplementary Data, Figure 2 .
Strength of the body of evidence
Using the GRADE system, we graded the SOE for AKI and CKD as low due to moderate study limitations, inconsistency and plausible confounding factors for the included studies. Meanwhile, AIN and ESRD were graded as insufficient because On the basis of systematic review estimates of 497 million CKD patients worldwide [46] .
they were subject to high study limitations, were imprecise and the number of studies were limited. AIN cases could not be classified as definite due to a limited report of histologic confirmations. Details of evidence synthesis and GRADE evidence profiles are shown in Supplementary Data, Table S21 .
D I S C U S S I O N
This systematic review and meta-analysis indicated that PPI use is associated with an increased risk of adverse kidney outcomes including AIN, AKI, CKD and ESRD. Although these findings challenge the value of PPIs in general practice, it should be noted that the strength of the body of evidence according to the GRADE system revealed low-or insufficient-quality evidence. Our study expanded a previous systematic review [53] of case reports/case series that examined the relationship between the use of PPIs and AIN by including experimental and observational studies. Despite a comprehensive review, we did not find any clinical controlled trials. We therefore synthesized the results of the included cohort and case-control studies reporting the association between PPI use and additional adverse kidney outcomes.
To date, PPIs are some of the most common causes of AIN, particularly in elderly patients [23, 55, 56] . However, the FIGURE 2: Risk ratio of kidney outcomes comparing PPI users versus non-PPI users. Forest plots showing risk ratio of (A) AKI and (B) CKD among PPI users compared with non-PPI users. AIN, acute interstitial nephritis; AKI, acute kidney injury; ARIC, Atherosclerosis Risk in Communities study; CI, confidence intervals; GHS, Geisinger Health System; IV, inverse variance; PPI, proton pump inhibitor; RR, risk ratio. [57, [58] [59] [60] . Interestingly, it has been reported that 30-70% of patients with AIN did not achieve complete kidney recovery after the discontinuation of PPIs [23, 58] . Partially recovered kidney function from PPI-induced AIN was reported in three biopsy-proven retrospective case series [23, 55, 61] . Consequently, it is speculated that undiagnosed, unrecognized and partial recovery from PPIinduced AIN could prime the kidney to develop subsequent AKI or CKD among PPI users [56] .
Recently, an interconnected syndrome between AKI and CKD and progression to ESRD was recognized in large observational studies and meta-analyses [62] [63] [64] [65] . AKI is a risk factor for CKD and CKD is a risk factor for developing AKI. Both share common risk factors and disease modifiers [62] . Although we found an association between PPI use and the risk of kidney progression, the results cannot be extrapolated to these interconnected conceptual models.
Several mechanisms are believed to explain the association between PPI use and the incidence of adverse kidney outcomes. A recent report by Yepuri et al. [66] , for example, demonstrated that long-term PPI use may impair endothelial function and accelerate endothelial senescence, subsequently increasing oxidative stress, endothelial dysfunction and vascular senescence and contributing to the pathogenesis of the progression of kidney disease. Furthermore, PPI-induced hypomagnesemia could explain the association between PPI use and CKD, because magnesium deficiency can increase the risk of kidney progression through endothelial cell dysfunction, inflammation and oxidative stress [67] [68] [69] [70] . In recent years, observational studies have shown that PPI use is associated with cardiovascular, neurological and kidney morbidity, which may reinforce the possibility of a mechanistic connection [21, 29, 30, 71] .
Given the increasing use of PPIs worldwide, the risk of adverse kidney outcomes among PPI users could pose a substantial disease and financial burden to the health care system. Indeed, our study estimated that approximately 0.3-0.7 million AKI cases and 9.9-24.4 million CKD cases worldwide were attributable to PPI use. As more than 50-70% of PPI prescriptions are deemed inappropriate, in terms of both inappropriate initiation without indications and prolonged use without appropriate medical conditions [11] [12] [13] 72] , the findings from our study support interventions or initiatives promoting appropriate PPI prescriptions, such as the Choosing Wisely PPI initiative and PPI deprescribing guidelines [1, 73, 74] .
Strengths and limitations
To our knowledge, this is the first systematic review and meta-analysis that reports the pooled association between PPI use and the risk of adverse kidney outcomes. This study was conducted using a rigorous and comprehensive approach without language restrictions and included a large number of participants. In addition, our sensitivity analyses, whereby H2RA users were used as an active comparator, showed consistent findings and confirmed a positive and significant association between PPI use and adverse kidney outcomes.
Several limitations of this review must be considered. First, despite a rigorous and comprehensive search, this meta-analysis is solely based on observational studies, which might be subject to selection bias and unmeasured confounders. Although several studies included sophisticated methods such propensity score analysis, confounding by indication and unmeasured confounders remain possible. In this regard, we concluded that the causality of PPI usage and adverse kidney outcomes cannot be established. Thus, caution should be employed when interpreting our findings.
Second, key baseline characteristics were not obtained across all included studies. Decreased estimated glomerular filtration rate and elevated albuminuria have been found to be associated with faster kidney disease progression [75] [76] [77] . However, only one study by Lazarus et al. [29] provided these data (Table 1 and Supplementary Data, Table S5 ). Another important limitation was that several studies allowed for concomitant medication use that might cause kidney deterioration, such as NSAIDs (range 5.4-86.7%, Supplementary Data, Table S8 ). This might affect the association between PPI use and adverse kidney outcomes.
Third, the included studies relied on electronic medical records and routinely collected administrative data, which might lead to information bias. Furthermore, we cannot verify the data on medication adherence over time, treatment indications and OTC prescriptions. Thus, misclassification bias should be noted.
Fourth, a moderate to high degree of inconsistency may limit our findings. We could not investigate the contribution of several studies regarding heterogeneity because of the small number of included studies. Additionally, various definitions of exposure and outcomes across studies may contribute to substantial heterogeneity between studies.
Finally, it is possible that publication bias exists. Although no evidence of asymmetry was found by the Begg's and Egger's tests, this method may be limited by the small number of included studies. However, after calibration with the trim and fill method, major findings remained unchanged.
Implications for public health and future research
Given the limited evidence, the results of this review represent the best available evidence that can inform the use of PPIs in general practice. Although the strength of the body of evidence and the magnitude of the association between the use of PPIs and the risk of kidney outcomes are small, the clinical importance of these findings should be stated due to the increasing use of PPIs and the growing incidence of AKI and CKD worldwide [45, 78] . Accordingly, clinicians should consider the clinical risk and potential benefits when prescribing PPIs. If prescribed, routine and proactive monitoring of kidney function during PPI use should be considered, particularly among patients with a pre-existing risk of kidney disease. To promote appropriate use of PPIs and reduce unnecessary economic consequences, a patient-centred program should be implemented. Patients should also be informed about the benefits and risks of PPIs.
Our findings underscore the need for further research to understand the association between the use of PPIs and kidney outcomes, especially long-term effects. Given their potential effects on kidney function, experimental animal models are also needed, which would help in understanding the pathogenesis and clarifying potential long-term effects. In addition, collaborative pharmacoepidemiological research and proactive post-marketing safety surveillance systems are required to assess whether the association between PPI use and kidney outcomes vary according to the individual PPI, PPI indications, patient age groups and medical history. The dose-and duration-response relationship between PPI use and kidney outcome also requires further exploration.
C O N C L U S I O N
Our findings illustrated that the use of PPIs may increase the risk of adverse kidney outcomes, particularly AKI and CKD, but the results were limited by suboptimal quality and heterogeneity of the included studies.
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